The first in class anti CD47 antibody Hu5F9 G4 is active and well tolerated alone or with azacitidine in AML and MDS patients Initial phase 1b results allergic reaction to doxycycline She was treated with trilostane with dosage increasing after most blood tests every 6 weeks until her sweet spot was found 6 months ago
The first in class anti CD47 antibody Hu5F9 G4 is active and well tolerated alone or with azacitidine in AML and MDS patients Initial phase 1b results allergic reaction to doxycycline She was treated with trilostane with dosage increasing after most blood tests every 6 weeks until her sweet spot was found 6 months ago